This week in drug discovery (2-6 December)
News round-up for 2-6 December by DDW Senior Digital Content Editor Diana Spencer.
This week’s leading news stories all shine a light on innovation within drug discovery, including a potential ‘best-in-industry’ weight loss drug, a gold-based compound that shrinks tumours by 82%, and a second-generation CAR-T therapy.
The top stories:
Next-generation therapy overcomes limitations of other CAR-T
A new chimeric antigen receptor T cell (CAR-T) therapy has delivered highly promising results in treating patients with relapsed/refractory B-cell acute lymphoblastic leukaemia (r/r B-ALL).
Gold-based drug slows tumour growth by 82%
Gold-based drugs can slow tumour growth in animals by 82% and target cancers more selectively than standard chemotherapy drugs, according to new research.
€11m supports launch of AI-powered drug development platform
Orakl Oncology has announced an €11 million seed funding round, led by Singular, with support from Bpifrance including the Grand Prix i-Lab, and participation from existing investors.
Two industry-first milestones for the exosome field
EXO Biologics (and its CDMO subsidiary, ExoXpert) has announced it has received Good Manufacturing Practice (GMP) certification for its manufacturing plant in Liège, Belgium.
€80 million financing will advance GIPR drugs for obesity
Biopharmaceutical company Antag Therapeutics has announced the closing of an €80 million Series A financing.